The general monograph for Tablets (0478) establishes mandatory quality standards and manufacturing requirements for all tablet dosage forms marketed in Europe. It is maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Scope and Definition
The European Pharmacopoeia (Ph. Eur.) Monograph 0478 defines the mandatory legal standards for the production, quality control, and testing of tablet dosage forms in Europe. It mandates specific tests for uniform dosage, disintegration (15 minutes for standard tablets), dissolution, and, if applicable, the subdivision of tablets to ensure patient safety and quality. For full details on the monograph requirements, visit EDQM .
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more ICH Q4B Annex 5 - Disintegration Test General Chapter - EMA European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
The European Pharmacopoeia (Ph. Eur.) is the authoritative standard for the quality control of medicines in Europe. is a general monograph , meaning it applies to the entire dosage form category rather than a specific chemical substance. It defines the fundamental standards for the manufacture, identification, testing, and storage of tablets intended for human and veterinary use.
This blog post provides an overview of the , which serves as the legally binding standard for tablets marketed in signatory states. This is for informational purposes only
The , titled "Tablets" (Compressi) , is the central general monograph establishing the mandatory quality standards for all tablet dosage forms in Europe. It provides the legal and scientific framework for their development, production, and marketing. Core Definition & Scope
Elena steered the conversation toward evidence. They reviewed pharmacokinetic models, pediatric swallowing studies, and adverse event reports. The dataset favored safer disintegration limits for younger populations. It was a familiar balance: public health benefit versus industry feasibility, both legitimate. In the end, their recommendation was pragmatic — adopt the stricter limit while allowing a transitional compliance period and providing validated test methods in the monograph’s commentary. both legitimate. In the end
Monograph 0478 imposes stricter criteria for non-standard tablets.